Riad Sherif, M.D., has served as the Chief Executive Officer and Director of Oculis since December 2017. Previously, from June 2016 to September 2017, Dr. Sherif served as Entrepreneur in Residence at the Novartis Venture Fund. Before that, Dr. Sherif served as the President of Europe, Middle East and Africa of Alcon, Inc. from March 2014 to May 2016. Prior to that, from January 2002 to April 2014, Dr. Sherif held roles of increasing responsibility at Novartis AG, including as the Global Sales Head in the Transplant and Infectious Disease unit, as the Head for Latin America in transplant and infectious disease, as the President of the Novartis Vaccines and Diagnostics Division for Latin America, and most recently as the President of Novartis Pharmaceuticals, Canada. Prior to Novartis, Dr. Sherif worked for several pharmaceutical companies, holding positions of increasing seniority, mainly in marketing and general management with international scope. Dr. Sherif currently serves as a member of the board of directors of Revenio Group corporation. Dr. Sherif previously served as the Vice Chairman for the Innovative Medicine Canada Association, as the Chairman of In-Vivo Montreal, and as the Chairman of the Board Ophthalmic Surgery and Vision Care of Eucomed. Dr. Sherif is a Medical Doctor by training, and holds an MBA from IMD Business School and a Specialized Master’s Degree in Medical Management from ESCP.

Sylvia Cheung, has served as the Chief Financial Officer of Oculis since September 2020. Prior to that, from October 2005 to August 2020, Ms. Cheung held executive positions at Anika Therapeutics, Inc., a publicly-traded joint preservation company. Most recently, from April 2013 to August 2020, Ms. Cheung served as the Chief Financial Officer of Anika Therapeutics, Inc. Previously, from 2000 to 2005, Ms. Cheung held a series of financial management positions of increasing responsibility at Transkaryotic Therapies, Inc., which was acquired by Shire Pharmaceuticals in 2005. Before that, from 1995 to 2000, Ms. Cheung served as a Senior Associate at PricewaterhouseCoopers. Ms. Cheung holds a Bachelor of Business Administration degree in Accounting from the University of Massachusetts in Amherst, an MBA from Boston University, and was certified as Certified Public Accountant in Massachusetts.

Virginia R. Dean, has been appointed as Chief Resources Officer of Oculis since February 2024. Prior to joining Oculis, she was Chief People Officer and Senior Vice President at Axcella Therapeutics from June 2021 to December 2022. Before this role, she founded ClearSight Leadership, Inc., a consulting firm, where she acted as Principal from January 2016 to June 2021. Prior to this entrepreneurial journey, she served as Vice President of Human Resources for several companies including for Tesaro, Inc., a public, oncology focused, commercial biotech, from December 2012 to December 2015, for Acronis, Inc., a privately held global SMB and enterprise businesses technology company, from September 2011 to November 2012, and for Ariad Pharmaceuticals, a publicly traded, oncology focused company, from June 2007 to December 2010. Before that, she held roles of increasing human resources responsibilities in various companies from 1995 to 2007 including for The Bridgespan Group, Macromedia, Inc., FleetBoston, and Towers Perrin. Ms. Dean received her M.B.A. from Simmons University and hold a B.A. in anthropology from the University of Vermont.

Bastian Dehmel, M.D., has served as Chief Development Officer of Oculis since January 2022. Previously, from October 2017 to December 2021, Dr. Dehmel served as the Chief Medical Officer of OxThera AB. Before that, from 2006 to July 2017, Dr. Dehmel held roles of increasing responsibility at Amgen, including as Senior Medical Manager, as International Medical Director, as Clinical Research Medical Director, and most recently, from December 2013 to July 2017, Dr. Dehmel served as Global Development Executive Medical Director of Amgen. Prior to that, from 2005 to 2006, Dr. Dehmel served as International Medical Advisor of NovoNordisk. Before that, from 2003 to 2005, Dr. Dehmel served as Medical Advisor Diabetes of GlaxoSmithKline Germany. Dr. Dehmel holds a Doctor of Medicine (M.D.) from Free University Berlin Medical School and received his clinical training in Internal Medicine at Charité University in Berlin, Germany.

Páll Ragnar Jóhannesson, has served as the Chief Business Officer of Oculis since September 2020. Previously, from January 2018 to September 2020, Mr. Jóhannesson served as the Chief Financial Officer of Oculis. Additionally, Mr. Jóhannesson has served as the Managing Director of Oculis Iceland ehf. since May 2015. Prior to that, from February 2012 to April 2015, Mr. Jóhannesson held a series of corporate finance positions of increasing responsibility at Straumur Investment Bank, and most recently, from September 2013 to April 2015, Mr. Jóhannesson served as the Managing Director, Corporate Finance. Before that, from January 2009 to November 2011, Mr. Jóhannesson served as a Director, Corporate Finance at Íslandsbanki and its predecessor Glitnir Bank. Mr. Jóhannesson holds a B.Sc. in Industrial Engineering from the University of Iceland, an M.Phil in Management Science from the University of Cambridge, and was certified as securities broker in Iceland.

Snehal Shah, Pharm D., has been appointed as the President, Research & Development of Oculis in April 2024. Before joining Oculis, Dr. Shah was serving as Chief Regulatory & Product Strategy Officer of Iveric Bio, Inc. from March 2021 to March 2024. During his tenure, the company was acquired by Astellas in 2023. Prior to Iveric Bio, he served as Senior Vice President, Regulatory Affairs and Pharmacovigilance at Kyowa Kirin from 2017 to 2021. He also held roles of increasing responsibilities in regulatory affairs and pharmacovigilance across various therapeutic areas at Noven Pharmaceuticals (Member of the Hisamitsu and Group) from 2012 to 2017 and at Hoffmann La-Roche/Genentech from 2007 to 2012.  Dr. Shah holds a B.S. in pharmacy from Rutgers University and a Doctorate of Pharmacy from the University of Kansas. He also completed the American Course of Drug Development and Regulatory Sciences Certification program at the University of California, San Francisco.

Rebecca Weil, Ph.D., has been appointed as the Chief Commercial Officer of Oculis in September 2023. Before joining Oculis, Ms. Weil served as Senior Vice President, Head of Global Marketing of Idorsia from July 2019 to August 2023. Prior to Idorsia, from February 2018 to March 2019, Ms. Weil served as Group Vice President, Head of Corporate Affairs and from August 2016 to February 2018, as Group Vice President, Global Franchise Head,  ophthalmology and neuroscience, at Shire.

Prior to Shire, she worked for several pharmaceutical companies holding roles of increasing responsibilities including as Vice President, Head of Western Europe of Alcon, as Pharma Franchise Head, Europe, Middle East, and Africa of Alcon, as Regional Franchise Head, Asia, Middle East, and Africa at Novartis, and as Global Head of Marketing and Strategy, Pharmaceuticals at Bausch & Lomb.

Ms. Weil started her career at McKinsey where she served as a Consultant and Engagement Manager.

Currently, she also serves as Trustee and Member of the Grants Committee of Scoliosis Association, UK and is a former Board Member of ARCHIVE Global (Architecture for Health in Vulnerable Environments) and the Juvenile Diabetes Research Foundation, New York Chapter.

Ms. Weil holds a Ph.D. in Political Science from the Massachusetts Institute of Technology (MIT), as well as a Bachelor of Arts from the Princeton University School of Public and International Affairs.